Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Authors:
- 1 January 2022
- journal article
- review article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (1) , 14-20
Abstract
No abstract availableKeywords
Funding Information
- Markey Cancer Center
This publication has 91 references indexed in Scilit:
- Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung CancerCancer Research, 2014
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Cancer Discovery, 2012
- Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential BiomarkerClinical Cancer Research, 2012
- Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- ABT-888 Confers BroadIn vivoActivity in Combination with Temozolomide in Diverse TumorsClinical Cancer Research, 2009
- Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine TumorsThe Oncologist, 2007
- Changing Face of Small-Cell Lung Cancer: Real and ArtifactJournal of Clinical Oncology, 2006
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002